The stock of IGC Pharma Inc (AMEX: IGC) has decreased by -1.03 when compared to last closing price of 0.34.Despite this, the company has seen a gain of 1.62% in its stock price over the last five trading days. accesswire.com reported 2025-01-08 that Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) (“IGC Pharma” or the “Company”) announced today that its ongoing Phase 2 trial for agitation in Alzheimer’s disease has been officially named CALMA (Calming Agitation in Alzheimer’s). The trial’s new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer’s patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.
Is It Worth Investing in IGC Pharma Inc (AMEX: IGC) Right Now?
Moreover, the 36-month beta value for IGC is 1.32. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IGC is 53.25M and currently, short sellers hold a 1.53% of that float. On January 08, 2025, IGC’s average trading volume was 349.11K shares.
IGC’s Market Performance
IGC’s stock has seen a 1.62% increase for the week, with a -7.49% drop in the past month and a -6.43% fall in the past quarter. The volatility ratio for the week is 7.20%, and the volatility levels for the past 30 days are at 7.83% for IGC Pharma Inc. The simple moving average for the past 20 days is -6.72% for IGC’s stock, with a -18.96% simple moving average for the past 200 days.
IGC Trading at -7.34% from the 50-Day Moving Average
After a stumble in the market that brought IGC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.47% of loss for the given period.
Volatility was left at 7.83%, however, over the last 30 days, the volatility rate increased by 7.20%, as shares sank -5.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.88% lower at present.
During the last 5 trading sessions, IGC rose by +2.65%, which changed the moving average for the period of 200-days by -8.27% in comparison to the 20-day moving average, which settled at $0.3662. In addition, IGC Pharma Inc saw 1.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IGC starting from Moran James P, who purchase 588,235 shares at the price of $0.34 back on Sep 25 ’24. After this action, Moran James P now owns 942,402 shares of IGC Pharma Inc, valued at $200,000 using the latest closing price.
PRINS RICHARD K, the Director of IGC Pharma Inc, proposed sale 200,000 shares at $0.39 during a trade that took place back on Aug 12 ’24, which means that PRINS RICHARD K is holding shares at $78,200 based on the most recent closing price.
Stock Fundamentals for IGC
Current profitability levels for the company are sitting at:
- -7.88 for the present operating margin
- 0.44 for the gross margin
The net margin for IGC Pharma Inc stands at -10.62. The total capital return value is set at -1.23. Equity return is now at value -117.06, with -93.54 for asset returns.
Based on IGC Pharma Inc (IGC), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -36.01.
Currently, EBITDA for the company is -9.16 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 21.3. The receivables turnover for the company is 13.44for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
Conclusion
To wrap up, the performance of IGC Pharma Inc (IGC) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
